Oregovomab

{{Short description|Monoclonal antibody}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458269412

| type = mab

| mab_type = mab

| source = o

| target = CA125

| tradename = OvaRex

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 213327-37-8

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = HX101E7L6S

| ATC_prefix = none

| ATC_suffix =

| ATC_supplemental =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D05269

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight = ca. 150 kg/mol

}}

Oregovomab (marketed under the trade name OvaRex) is a mouse monoclonal antibody it binds to the antigen CA125, a carbohydrate antigen. It is designed for the treatment of ovarian cancer.{{cite web | title = Statement on a Nonproprietary Name Adopted by the USAN Council - Oregovomab | url = http://www.ama-assn.org/ama/upload/mm/365/oregovomab.doc | archive-url = http://web.archive.org/web/20030814091910/http://www.ama-assn.org/ama/upload/mm/365/oregovomab.doc | archive-date = 14 August 2003 | publisher = American Medical Association }}{{cite journal | vauthors = Pietragalla A, Duranti S, Daniele G, Nero C, Ciccarone F, Lorusso D, Fagotti A, Scambia G | title = Oregovomab: an investigational agent for the treatment of advanced ovarian cancer | journal = Expert Opinion on Investigational Drugs | volume = 30 | issue = 2 | pages = 103–110 | date = February 2021 | pmid = 33423551 | doi = 10.1080/13543784.2021.1868436 }}

This drug was developed by AltaRex Corp.